Orion Pharma to Unveil First Clinical Data for TEAD Inhibitor ODM-212 at ASCO 2026
Event summary
- Orion Pharma will present first clinical data from Phase 1/2 TEADES trial of ODM-212 at ASCO 2026.
- ODM-212 is an investigational oral pan-TEAD inhibitor targeting the Hippo signaling pathway.
- TEADES trial enrolls up to 300 patients with advanced solid tumors, including mesothelioma and EHE.
- Primary endpoints are safety and tolerability; secondary endpoints include Overall Response Rate and Progression Free Survival.
- Presentation scheduled for May 30, 2026, during the Developmental Therapeutics session.
The big picture
Orion Pharma's presentation at ASCO 2026 marks a critical milestone in the development of ODM-212, a novel TEAD inhibitor targeting the Hippo pathway. The data could validate Orion's approach to treating advanced solid tumors with high unmet medical needs, positioning the company in the competitive oncology space. Success in this trial may open doors for combination therapies and broader applications in cancer treatment.
What we're watching
- Clinical Efficacy
- How the preliminary anti-tumor activity data will position ODM-212 against existing therapies.
- Regulatory Pathway
- Whether the Phase 1/2 data will support accelerated development or combination therapy strategies.
- Market Differentiation
- The pace at which Orion can establish ODM-212 as a leading TEAD inhibitor in the oncology space.
Related topics